Biotechnology

A new partnership introduces PBSerum®, a biologically inspired enzyme treatment, aiming to redefine skin quality in the multi-billion dollar aesthetics market.

New data shows Imofinostat turns 'cold' colorectal tumors 'hot' for immunotherapy and breaks chemo-resistance in pancreatic cancer, fueling pivotal trials.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

Replimune halts a promising cancer therapy and cuts jobs after a stunning FDA rejection, citing a 'failed' system and inconsistent regulatory process.

Allogene Therapeutics faces a make-or-break moment as it prepares to unveil crucial trial data for its 'off-the-shelf' cancer therapy, cema-cel.

Lupin has launched a generic version of the blockbuster diabetes drug Farxiga, signaling lower costs for patients and a major shake-up in the SGLT2 market.

A new partnership between a Chinese biotech and a Brazilian public institute aims to slash the $500k cost of CAR-T therapy, making it accessible to all.

A new study shows the feasibility of a single device for glucose monitoring and insulin delivery, aiming to simplify life for millions with diabetes.

With a massive $54M Series A, Vivatides Therapeutics aims to solve RNA's biggest delivery problem, unlocking new treatments for a host of chronic diseases.

At analytica 2026, Haier Biomedical unveiled its 'In Europe, For Europe' strategy, challenging market leaders with integrated solutions and local roots.

A new partnership combines local infrastructure with global expertise, aiming to streamline development for startups and solidify Singapore's biotech leadership.

Ditching the static model, CleanSpace is building a full-scale, operational pharmaceutical factory on the tradeshow floor, a move set to transform B2B marketing.

Powered Research will unveil an AI that speeds drug testing for retinal diseases and key findings on animal models, aiming to transform preclinical studies.

Five new clinical trials in Chicago repurpose existing drugs for PTSD, cancer, and more, offering a faster, cheaper path to treating unsolved diseases.

In a significant move, 35 workers at a key biopharmaceutical firm supporting the CDC and FDA have unionized, highlighting new frontiers for organized labor.

With late-stage trials for two common eye conditions affecting millions, Cloudbreak Pharma is advancing novel drops where no approved drugs exist.

Positive Phase 1b data for two novel drugs suggests a long-acting, once-monthly oral therapy for recurrent genital herpes may be on the horizon.

As drug-resistant superbugs threaten modern medicine, a novel liquid therapeutic from Seres Therapeutics offers a lifeline for the most vulnerable patients.

Behavior Labs launches a new platform to close the life sciences' 'ground truth gap,' replacing slow quarterly reviews with continuous, daily intelligence.

With Christoph Korpus at the helm, Byondis signals a strategic shift to accelerate its innovative cancer therapies through new partnerships and commercialization.